The cutting edge: Thalidomide for type 1 cryoglobulinemic vasculopathy.
Sampson
Alia
A
Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Callen
Jeffrey P
JP
D000284:Administration, Oral; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D003449:Cryoglobulinemia / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D035002:Lower Extremity; D017445:Skin Diseases, Vascular / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide